Locate Bio Raises £9.2m for LDGraft ALIF Study – Locate Bio
Summary
The proceeds will fund a clinical study of LDGraft, a bone graft substitute for spinal fusion.This funding and the clinical trial known as RESTORE (A Randomized Study of LDGraft in Single Level Anterior Lumbar Interbody Fusion) marks a significant milestone in the companys mission to relieve suffering and restore the quality of life for millions of patients suffering from debilitating orthopaedic conditions worldwide.Locate Bio combines decades of research in advanced drug delivery systems and utilises a proprietary protein encapsulation method to deliver a powerful therapeutic protein called rhBMP-2. With the rapidly ageing global population, there is an urgent need for products that address chronic, progressive, and debilitating back pain, added von Benecke. The RESTORE clinical trial is an important step towards realising that ambition.Locate Bio has demonstrated significant progress in its drive towards developing innovative solutions that address a wide range of musculoskeletal needs. The Group has 11 offices in the UK and Mercia Ventures national footprint and 48 strong investment team draws on their experiences as founders, PhD scientists, software engineers, corporate financiers and management consultants to help its partner companies successfully achieve their ambitions. BGF is a minority, non-controlling equity partner with a patient outlook on investments, based on shared long-term goals with the management teams it backs.